We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Helicos Unveils 'Early Access' Availability of tSMS™ Technologies
News

Helicos Unveils 'Early Access' Availability of tSMS™ Technologies

Helicos Unveils 'Early Access' Availability of tSMS™ Technologies
News

Helicos Unveils 'Early Access' Availability of tSMS™ Technologies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Helicos Unveils 'Early Access' Availability of tSMS™ Technologies "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Helicos BioSciences has announced that it would begin partnering with a selected group of experimental researchers, providing access to its True Single Molecule Sequencing (tSMS™) technologies and techniques in support of research projects.

Helicos' "Early Access" partners may publish their findings from utilizing tSMS™ technologies, as well as present at scientific conferences.

Stanley N. Lapidus, President and CEO of Helicos BioSciences, said, "We are very proud to begin providing access to applications in tSMS™ to a small group of innovative research partners."

"This marks the first time in history that tSMS™ based applications will be open to the experimental community."

He added, "Our intention is to work closely with top researchers and thought leaders to demonstrate the full advantages of leveraging tSMS™ in unlocking experimental possibilities that were inconceivable up to now."

"We look forward to very intriguing and compelling results from these collaborations."

Advertisement